Draxxin® 25 now available for convenient use in small pigs
Zoetis releases lower concentration formula optimized for use in nursery
FLORHAM PARK, N.J., Nov. 4, 2013 — DRAXXIN® 25 (tulathromycin) Injectable Solution is now available from Zoetis — offering a convenient tool to fight swine respiratory disease (SRD) in nursery pigs. DRAXXIN 25 is a lower concentration of DRAXXIN, making it optimized for use in small pigs to treat and control SRD with nine days of protection.
“Our customers know how effective DRAXXIN is for larger pigs, but they told us they wanted a more convenient solution to make treating nursery-size pigs easier,” said Michael Senn, DVM, senior manager, Pork Technical Services, Zoetis. “DRAXXIN 25 offers the same trusted and proven performance as DRAXXIN, now in the lower concentration producers and veterinarians need for the nursery.”
For DRAXXIN 25, a 1 mL intramuscular dose is formulated for 22 pounds of weight. DRAXXIN, in comparison, is formulated for a 1 mL dose per 88 pounds of weight. With the lower concentration, DRAXXIN 25 offers easier, more confident administration in smaller pigs.
In one study, producers identified respiratory problems as the cause of more than half of all nursery pig deaths.1 Along with high mortality rates, complex SRD also can hurt production because of lower feed efficiency, higher cull rates and higher treatment costs.
“DRAXXIN 25 meets the unique challenges of caregivers and the smaller pigs that depend on them,” Dr. Senn said. “Producers and veterinarians can be confident that their small pigs are getting the correct amount of protection they need.”
Like DRAXXIN, one dose of DRAXXIN 25 delivers nine full days of lung activity to treat and control SRD.2-3 DRAXXIN 25 treats the five major bacterial SRD-causing pathogens — Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis and Mycoplasma hyopneumoniae — and helps control SRD in groups where SRD has been diagnosed and is associated with A. pleuropneumoniae, P. multocida and M. hyopneumoniae.
DRAXXIN 25 is available in 100-mL and 250-mL vials and may be purchased through your veterinarian or animal health retailer with a veterinarian’s prescription. DRAXXIN 25 is also backed by the Vial Guarantee, which protects your investment by replacing broken or stolen bottles.
For more information on DRAXXIN 25, visit zoetispork.com/DRAXXIN25 or visit with your veterinarian or local Zoetis representative.
Important Safety Information: The pre-slaughter withdrawal time for DRAXXIN and DRAXXIN 25 in swine is five days. DRAXXIN and DRAXXIN 25 should not be used in animals known to be hypersensitive to the product.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide at the beginning of 2013, Zoetis has a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information on the company, visit www.zoetisUS.com.
Zoetis is the proud sponsor with the Smithsonian Institution Traveling Exhibition Service and the American Veterinary Medical Association of the mobile educational exhibit Animal Connections: Our Journey Together. Families visiting the exhibit will explore the vast bonds between people and animals and learn about the important role veterinarians play in protecting animal and human health.
For further information, Contact:
Bader Rutter & Associates
1 U.S. Department of Agriculture. Swine 2006, Part III: Reference of Swine Health, Productivity, and General Management in the United States, 2006. Fort Collins, CO. 2006 N478.0308.
2 Scheidt A. DRAXXIN® (tulathromycin) Injectable Solution: Duration of effectiveness in an Actinobacillus pleuropneumoniae challenge model. Technical Bulletin No. DXS06040, New Jersey: Zoetis, 2007.
3 Benchaoui HA, Nowakowski M, Sherington J, Rowan TG, Sunderland SJ. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther 2004;27(4):203-210.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States